دورية أكاديمية
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
العنوان: | Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial |
---|---|
المؤلفون: | Thiery-Vuillemin, Antoine, de Bono, Johann, Hussain, Maha, Roubaud, Guilhem, Procopio, Giuseppe, Shore, Neal, Fizazi, Karim, dos Anjos, Gabriel, Gravis, Gwenaelle, Joung, Jae Young, Matsubara, Nobuaki, Castellano, Daniel, Degboe, Arnold, Gresty, Chris, Kang, Jinyu, Allen, Allison, Poehlein, Christian, Saad, Fred |
المساهمون: | Merck, Merck Sharp and Dohme, AstraZeneca |
المصدر: | The Lancet Oncology ; volume 23, issue 3, page 393-405 ; ISSN 1470-2045 |
بيانات النشر: | Elsevier BV |
سنة النشر: | 2022 |
المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
مصطلحات موضوعية: | Oncology |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
DOI: | 10.1016/s1470-2045(22)00017-1 |
الإتاحة: | https://doi.org/10.1016/s1470-2045Test(22)00017-1 https://api.elsevier.com/content/article/PII:S1470204522000171?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S1470204522000171?httpAccept=text/plainTest |
حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://www.elsevier.com/open-access/userlicense/1.0Test/ ; https://doi.org/10.15223/policy-017Test ; https://doi.org/10.15223/policy-037Test ; https://doi.org/10.15223/policy-012Test ; https://doi.org/10.15223/policy-029Test ; https://doi.org/10.15223/policy-004Test |
رقم الانضمام: | edsbas.A3CFBF12 |
قاعدة البيانات: | BASE |
DOI: | 10.1016/s1470-2045(22)00017-1 |
---|